Advertisement

Management of Patients with Increased Fracture Risk

  • Felicia Cosman
Chapter

Abstract

Osteoporosis is often diagnosed in women and men in the sixth decade of life, resulting in up to 40 years during which bone loss progresses and fracture risk increases. Therefore, treatment decisions for osteoporosis should consider not just whether to treat but also what is the most rational approach to long-term control of the disease, with the goals of minimizing fracture risk while also minimizing risk of adverse events. Different medications are more appropriate at different ages and severity of the disease. Furthermore, proof of efficacy for any therapy beyond 5 years is limited, and some adverse events with potent anti-resorptive medication might be associated with duration of treatment. No osteoporosis medication should be used forever, and sequential monotherapy, rotating effective agents, is the most logical approach for most individuals. This chapter provides a rationale for treatment decisions at different ages and stages of osteoporosis and discusses treatment sequences that are most likely to achieve the greatest therapeutic margin. The chapter will also cover a rationale for consideration of stopping therapy (and how to determine when and if to restart therapy). Finally, the chapter discusses the circumstances in which combination therapy should be considered.

Keywords

Fracture risk Osteoporosis Anti-resorptive medication Sequential monotherapy Drug holiday Treatment duration Bone mineral density 

References

  1. 1.
    Harvey N, Dennison E, Cooper C. The epidemiology of osteoporotic fractures. In: Rosen CJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. UK: Wiley-Blackwell; 2013. p. 348–56.CrossRefGoogle Scholar
  2. 2.
    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637–45.CrossRefGoogle Scholar
  3. 3.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefGoogle Scholar
  4. 4.
    Cummings SR, Ensrud K, Delmas PD, LaCroix AZ, Vukicevic S, Reid DM, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686–96.CrossRefGoogle Scholar
  5. 5.
    Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696–706.CrossRefGoogle Scholar
  6. 6.
    Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799–809.CrossRefGoogle Scholar
  7. 7.
    Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY, et al. Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int. 2015;26(12):2763–71.CrossRefGoogle Scholar
  8. 8.
    Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cosman F, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27(2):243–54.CrossRefGoogle Scholar
  9. 9.
    Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27(3):645–53.CrossRefGoogle Scholar
  10. 10.
    Schousboe JT, Fink HA, Lui LY, Taylor BC, Ensrud KE. Association between prior non-spine non-hip fractures or prevalent radiographic vertebral deformities known to be at least 10 years old and incident hip fracture. J Bone Miner Res. 2006;21(10):1557–64.CrossRefGoogle Scholar
  11. 11.
    van Geel TA, Huntjens KM, van den Bergh JP, Dinant G-J, Geusens PP. Timing of subsequent fractures after an initial fracture. Curr Osteoporos Rep. 2010;8(3):118–22.CrossRefGoogle Scholar
  12. 12.
    Kendler DL, Marin F, Zerbini CA, Russo LA, Greenspan SL, Zikan V, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018;391(10117):230–40.CrossRefGoogle Scholar
  13. 13.
    Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359–81.CrossRefGoogle Scholar
  14. 14.
    Cosman F. Combination therapy for osteoporosis: a reappraisal. BoneKEy Rep. 2014;3:518.CrossRefGoogle Scholar
  15. 15.
    Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320–3.CrossRefGoogle Scholar
  16. 16.
    Johnell O, Kanis JA, Oden A, Sernbo I, Redlund-Johnell I, Petterson C, et al. Fracture risk following an osteoporotic fracture. Osteoporos Int. 2004;15(3):175–9.CrossRefGoogle Scholar
  17. 17.
    Huntjens KM, Kosar S, van Geel TA, Geusens PP, Willems P, Kessels A, et al. Risk of subsequent fracture and mortality within 5 years after a non-vertebral fracture. Osteoporos Int. 2010;21(12):2075–82.CrossRefGoogle Scholar
  18. 18.
    Center JR, Bliuc D, Nguyen TV, Eisman JA. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387–94.CrossRefGoogle Scholar
  19. 19.
    Cosman F, Nieves JW, Dempster DW. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res. 2017;32(2):198–202.CrossRefGoogle Scholar
  20. 20.
    Cosman F. Anabolic and antiresorptive therapy for osteoporosis: combination and sequential approaches. Curr Osteoporos Rep. 2014;12(4):385–95.CrossRefGoogle Scholar
  21. 21.
    Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, et al. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet. 2015;386(9999):1147–55.CrossRefGoogle Scholar
  22. 22.
    Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513–23.CrossRefGoogle Scholar
  23. 23.
    Cosman F, Wermers RA, Recknor C, Mauck KF, Xie L, Glass EV, et al. Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. J Clin Endocrinol Metab. 2009;94(10):3772–80.CrossRefGoogle Scholar
  24. 24.
    Cosman F, Keaveny TM, Kopperdahl D, Wermers RA, Wan X, Krohn KD, et al. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene. J Bone Miner Res. 2013;28(6):1328–36.CrossRefGoogle Scholar
  25. 25.
    Tsai JN, Uihlein AV, Lee H, Kumbhani R, Siwila-Sackman E, McKay EA, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382(9886):50–6.CrossRefGoogle Scholar
  26. 26.
    Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296(24):2927–38.CrossRefGoogle Scholar
  27. 27.
    Cosman F, Cauley JA, Eastell R, Boonen S, Palermo L, Reid IR, et al. Reassessment of fracture risk in women after 3 years of treatment with zoledronic acid: when is it reasonable to discontinue treatment? J Clin Endocrinol Metab. 2014;99(12):4546–54.CrossRefGoogle Scholar
  28. 28.
    Brown JP, Roux C, Torring O, Ho PR, Beck Jensen JE, Gilchrist N, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746–52.CrossRefGoogle Scholar
  29. 29.
    Freemantle N, Satram-Hoang S, Tang ET, Kaur P, Macarios D, Siddhanti S, et al. Final results of the DAPS (Denosumab Adherence Preference Satisfaction) study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women. Osteoporos Int. 2012;23(1):317–26.CrossRefGoogle Scholar
  30. 30.
    Boonen S, Ferrari S, Miller PD, Eriksen EF, Sambrook PN, Compston J, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspective. J Bone Miner Res. 2012;27(5):963–74.CrossRefGoogle Scholar
  31. 31.
    Reid IR, Black DM, Eastell R, Bucci-Rechtweg C, Su G, Hue TF, et al. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams. J Clin Endocrinol Metab. 2013;98(2):557–63.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Helen Hayes HospitalWest HaverstrawUSA

Personalised recommendations